Literature DB >> 17425666

Tissue factor around dermal vessels has bound factor VII in the absence of injury.

M Hoffman1, C M Colina, A G McDonald, G M Arepally, L Pedersen, D M Monroe.   

Abstract

BACKGROUND: 'Idling' or ongoing low-level activity of the tissue factor (TF) pathway is a postulated mechanism by which the coagulation process can become active without a lag period at sites of injury.
OBJECTIVE: To determine whether TF around cutaneous vessels has bound factor VIIa in the absence of injury, and thus could participate in the idling process.
METHODS: Immunostaining of mouse skin with antibodies against a 15-residue peptide from the sequence of mouse TF, and against the whole extracellular portion of TF.
RESULTS: The whole TF antibody recognized TF in squamous epithelium and around vessels in the dermis. By contrast, the monospecific antibody only recognized TF in the squamous epithelium, but not around vessels. We also found that biotinylated, active site-inhibited FVIIa (FVIIai) bound to tissue sections in the same areas in which TF was recognized by the monospecific antibody (squamous epithelium), but did not bind around vessels. Molecular modeling revealed that FVIIa and FX binding to TF masked a significant part of the surface of the target peptide.
CONCLUSIONS: In the aggregate, these data are most consistent with the interpretation that TF in perivascular sites has bound FVIIa, even in the absence of any injury. The presence of endogenously bound FVIIa prevents the subsequent binding of the monospecific antibody or exogenous FVIIai to perivascular TF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425666     DOI: 10.1111/j.1538-7836.2007.02576.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

1.  The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.

Authors:  Giulia Pavani; Lacramioara Ivanciu; Armida Faella; Oscar A Marcos-Contreras; Paris Margaritis
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

2.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

Review 3.  Coagulation in liver toxicity and disease: role of hepatocyte tissue factor.

Authors:  Anna K Kopec; James P Luyendyk
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

4.  Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases.

Authors:  Shiro Koizume; Naho Yokota; Etsuko Miyagi; Fumiki Hirahara; Yoshiyasu Nakamura; Yuji Sakuma; Akira Yoshida; Yoichi Kameda; Eiju Tsuchiya; Wolfram Ruf; Yohei Miyagi
Journal:  Mol Cancer Res       Date:  2009-12-08       Impact factor: 5.852

Review 5.  Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited.

Authors:  Alisa S Wolberg; Maria M Aleman; Karin Leiderman; Kellie R Machlus
Journal:  Anesth Analg       Date:  2011-11-21       Impact factor: 5.108

6.  Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor.

Authors:  Y Z Ohkubo; J H Morrissey; E Tajkhorshid
Journal:  J Thromb Haemost       Date:  2010-02-24       Impact factor: 5.824

7.  Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).

Authors:  R Gopalakrishnan; U Hedner; S Ghosh; R C Nayak; T C Allen; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

Review 8.  The many faces of tissue factor.

Authors:  N Mackman
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 9.  The role of tissue factor and factor VIIa in hemostasis.

Authors:  Nigel Mackman
Journal:  Anesth Analg       Date:  2009-05       Impact factor: 5.108

10.  Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).

Authors:  Mariasanta Napolitano; Muriel Giansily-Blaizot; Alberto Dolce; Jean F Schved; Guenter Auerswald; Jørgen Ingerslev; Jens Bjerre; Carmen Altisent; Pimlak Charoenkwan; Lisa Michaels; Ampaiwan Chuansumrit; Giovanni Di Minno; Umran Caliskan; Guglielmo Mariani
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.